145692-57-5

Basic information

• Product Name: 1H-INDOLE-3-CARBONITRILE, 6-METHOXY-
• Synonyms: 1H-INDOLE-3-CARBONITRILE, 6-METHOXY-;6-methoxy-1H-indole-3-carbonitrile;3-CYANO-6-METHOXY-1H-INDOLE
• CAS NO: 145692-57-5
• Molecular Formula: C10H8N2O
• Molecular Weight: 172.18
• Mol File: 145692-57-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 385 °C at 760 mmHg
• Flash Point: 186.6 °C
• Appearance: /
• Density: 1.26
• Refractive Index: 1.64
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-INDOLE-3-CARBONITRILE, 6-METHOXY-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDOLE-3-CARBONITRILE, 6-METHOXY-(145692-57-5)
• EPA Substance Registry System: 1H-INDOLE-3-CARBONITRILE, 6-METHOXY-(145692-57-5)

Safety Data

• Hazardous Substances Data: 145692-57-5(Hazardous Substances Data)

Usage

General Description

1H-Indole-3-carbonitrile, 6-methoxy- is a chemical compound with the molecular formula C10H8N2O. It is a derivative of indole and contains a nitrile group and a methoxy group. 1H-INDOLE-3-CARBONITRILE, 6-METHOXY- is commonly used in organic synthesis as a building block for the production of various pharmaceuticals, agrochemicals, and dye intermediates. It is known to exhibit a range of biological activities, including anti-cancer, anti-inflammatory, and anti-microbial properties. Additionally, 1H-Indole-3-carbonitrile, 6-methoxy- has been studied for its potential use as a precursor in the production of novel therapeutic agents.

InChI:InChI=1/C10H8N2O/c1-13-8-2-3-9-7(5-11)6-12-10(9)4-8/h2-4,6,12H,1H3

Upstream product

• 70555-46-3 6-methoxy-1H-indole-3-carbaldehyde 
• 3189-13-7 6-methoxylindole 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 1261024-50-3 6-methoxy-1H-indole-3-carbaldehyde oxime 

Downstream Products

• 1248576-70-6 (S)-6-(3-cyano-1-cyclobutyl-6-(difluoromethoxy)-1H-indol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide 
• 1248585-37-6 C₂₆H₃₈F₂N₂OSn 
• 876739-47-8 C₁₉H₁₈FN₃O 
• 1443382-52-2 C₁₉H₁₇N₃O₂ 
• 1443382-51-1 C₁₉H₁₈N₂O₂S 
• 1443382-53-3 C₂₅H₂₁N₃O₂ 
• 876733-61-8 2-(4-aminophenyl)-1-ethyl-6-methoxy-1H-indole-3-carbonitrile 

Relevant articles and documents

Metabolism of the phytoalexins camalexins, their bioisosteres and analogues in the plant pathogenic fungus Alternaria brassicicola

The metabolism of the phytoalexins camalexin (1), 1-methylcamalexin (10) and 6-methoxycamalexin (11) by Alternaria brassicicola and their antifungal activity is reported. This work establishes that camalexins are slowly biotransformed (ca. six days) to the corresponding indole-3-thiocarboxamides, which are further transformed to the indole-3-carboxylic acids. These metabolites are substantially less inhibitory to A. brassicicola than the parent camalexins, indicating that these enzyme-mediated transformations are detoxifications. In addition, analyses of the metabolism of synthetic isomers and bioisosteres of camalexin (1) indicate that isomers of camalexin in the thiazole ring are not metabolized. Based on these results, the potential intermediates that lead to formation of indole-3-thiocarboxamides are proposed.

Discovery of N-(4′-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication

A series of novel 2-phenylindole analogs were synthesized and evaluated for activity in subgenomic HCV replicon inhibition assays. Several compounds containing small alkyl sulfonamides on the phenyl ring exhibiting submicromolar EC50 values against the genotype 1b replicon were identified. Among these, compound 25d potently inhibited the 1b replicon (EC50 = 0.17 μM) with 147-fold selectivity with respect to cytotoxicity. Compound 25d was stable in the presence of human liver microsomes and had a good pharmacokinetic profile in rats with an IV half-life of 4.3 h and oral bioavailability (F) of 58%.

NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4) ; Y2 represents N or C(R5) ; R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxygroup or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, ahalogenatometc.; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.